Outlook Therapeutics, Inc.
NASDAQ:OTLK
1.825 (USD) • At close February 4, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 8.146 | 3.088 | 3.812 | 2.98 | 5.219 | 9.051 |
| Cost of Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0.997 | 0.994 | 0.994 | 0.989 | 0.993 | 0.998 |
| Reseach & Development Expenses
| 41.763 | 26.453 | 42.331 | 38.958 | 26.342 | 23.805 | 18.504 | 23.81 | 32.763 | 38.876 | 14.125 |
| General & Administrative Expenses
| 29.94 | 26.673 | 20.74 | 12.769 | 9.971 | 9.37 | 14.228 | 15.882 | 21.564 | 12.906 | 7.318 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 29.94 | 26.673 | 20.74 | 12.769 | 9.971 | 9.37 | 14.228 | 15.882 | 21.564 | 12.906 | 7.318 |
| Other Expenses
| 0 | -3.756 | -0.883 | 0 | 0 | 11.27 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 71.703 | 53.126 | 63.071 | 51.727 | 36.313 | 44.445 | 32.732 | 39.692 | 54.327 | 51.782 | 21.443 |
| Operating Income
| -71.703 | -53.126 | -63.071 | -51.727 | -36.841 | -36.299 | -29.644 | -35.88 | -51.347 | -46.563 | -12.392 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | -4.456 | -8.241 | -9.414 | -17.371 | -8.921 | -1.369 |
| Total Other Income Expenses Net
| -3.661 | -4.294 | -1.491 | -0.498 | -0.442 | -1.636 | -4.096 | -2.467 | -1.852 | -2.297 | -0.901 |
| Income Before Tax
| -75.364 | -58.98 | -66.049 | -53.161 | -38.511 | -37.935 | -33.74 | -38.348 | -53.199 | -48.86 | -13.293 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | -4.657 | -10.928 | -10.061 | -17.864 | -9.362 | -1.469 |
| Income Tax Expense
| 0 | 0.003 | 0.003 | 0.002 | -3.272 | -3.411 | -3.648 | 0.502 | 0.103 | -0.19 | 0.439 |
| Net Income
| -75.367 | -58.983 | -66.052 | -53.163 | -35.239 | -34.524 | -30.092 | -38.849 | -53.302 | -47.393 | -13.732 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | -4.238 | -14.936 | -10.193 | -17.898 | -9.081 | -1.517 |
| EPS
| -9.84 | -4.72 | -6.23 | -6.96 | -9.71 | -37.96 | -50.7 | -258.75 | -495.71 | -504.47 | -155.35 |
| EPS Diluted
| -9.76 | -4.72 | -6.23 | -6.96 | -9.71 | -37.96 | -50.7 | -258.54 | -495.71 | -504.47 | -155.35 |
| EBITDA
| -71.589 | -56.849 | -63.798 | -51.511 | -35.759 | -31.106 | -26.795 | -30.03 | -48.953 | -44.738 | -11.514 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | -2.66 | -7.252 | -8.707 | -16.567 | -8.572 | -1.272 |